Decreased FXR activity attenuates suppression of SREBP1c‐mediated lipogenesis and dysregulates CYP7A1 expression, collectively promoting hepatic lipid accumulation, inflammation, and MASLD progression [168]. This evidence concerns the gene CYP7A1 and metabolic dysfunction-associated steatotic liver disease.